A new commentary published in The Lancet Regional Health – Europe argues that this machinery is in trouble. Written by Gijs Geleijnse of the Netherlands Comprehensive Cancer Organisation and colleagues from cancer registries and research institutions across the continent, the piece lays out a stark diagnosis: despite decades of investment in healthcare digitalisation and the ongoing preparation of the European Health Data Space, the infrastructure underpinning Europe’s cancer registries is frail. Coverage of the continent remains suboptimal, the timeliness of data publication varies widely from country to country, and registries themselves repeatedly cite resource limitations as the main barrier to investing in innovation. The result is a system that cannot reliably answer even basic questions about the state of cancer in Europe today.

The stakes are rising fast. Through the European Cancer Information System, known as ECIS, the registries of the European Network of Cancer Registries reveal cancer inequalities within and between European geographies, showing where progress is being made and where attention is urgently required. But the financial context is shifting beneath them. Cancer spending in Europe is expected to rise by 59 percent by 2050, according to an analytical report from the OECD and the European Commission. Registries are uniquely positioned to guide how that money is spent—supporting the effective allocation of resources and the implementation and evaluation of cancer prevention, early detection and quality of care—yet only if the data they deliver are complete, comparable and current.

One of the most striking asymmetries highlighted in the commentary is regulatory. Many European countries have national legislation on cancer registration, but there is no European regulation governing PBCR-based statistics. That stands in sharp contrast to mortality statistics, which are governed by explicit EU regulation and delivered by national statistics bureaus and Eurostat, ensuring timely and comparable collection of cause-of-death data across the Union. In other words, Europe legally guarantees that it knows how many people die of cancer and where, but not that it knows how many are diagnosed, how they are treated, or whether they survive. For a continent that has made cancer control a flagship policy priority, the gap is difficult to justify.

The technical picture is equally uneven. Europe’s 192 population-based cancer registries follow the registration guidelines issued by the European Commission’s Joint Research Centre together with the ENCR, but their capacity to collect timely, high-quality data varies enormously. Some registries struggle to record basic clinical elements such as stage at diagnosis and the treatments patients actually received—variables that are indispensable for measuring early detection programmes and the quality of care. A survey of registries published in the International Journal of Cancer in 2025 documented this global capacity gap, and recent work mapping European registries has shown that coverage, data availability and the ability to generate real-world evidence differ substantially across the continent.

The timing of the warning matters. The Joint Action CancerWatch, running from 2025 to 2028 with the participation of 92 organisations from 29 countries, aims specifically to improve the timeliness and quality of the registry data feeding into ECIS. The project exists precisely because geographic coverage is incomplete and timely indicators are limited on the platform. Meanwhile, the European Court of Auditors has called for a monitoring framework for the European Commission’s Beating Cancer Plan, noting in a 2026 special report that the wide-ranging plan faces an uncertain future. ECIS was established to monitor the cancer burden in Europe, but the current limitations in registry data infrastructure undermine its ability to fulfil that role. A monitoring plan without a functioning measurement system, the authors imply, is a promise without a receipt.

To close the gap, the commentary sets out a layered set of policy options. At EU level, the authors call for formal recognition of population-based cancer registries as core components of public health systems, an endorsement that would echo the Council Recommendation on strengthening prevention through early detection, which gave EU cancer screening programmes a firm regulatory footing. The European Commission, they argue, should publish explicit criteria for the data quality and timeliness required for registry data on ECIS, so that the quality and progress of cancer registration in member states can be monitored and managed transparently. Under the European Health Data Space Regulation, they further propose a data usage fee for registries that prioritise delivering data and statistics to ECIS—turning registries from passive data suppliers into recognised, resourced participants in the European data economy.

The integration agenda goes further. Registries, the authors contend, should be built into cancer screening programmes and comprehensive cancer centres as an integral element rather than an afterthought, and future EU project proposals on these topics should require the involvement and adequate resourcing of registries for planning, monitoring and evaluation. At member state level, each country should designate an organisation responsible for delivering national registry data to ECIS, acting as the link between EU bodies and regional registries and embedded in the design and monitoring of the national Cancer Mission Hubs. Sustainable funding is only part of the answer: national innovation funds earmarked for artificial intelligence and digital sovereignty should, the authors argue, also support innovation within registries, which are precisely the kind of high-value, privacy-preserving data infrastructure those funds are meant to cultivate.

At the registry level itself, the recommendations are more sober but no less important. Registries should obtain a formal mandate from their governments as a core component of public health and cancer control, giving them the legal standing to negotiate data access and funding. They should also allocate resources to increase the efficiency of data collection and publication—modernising the often manual, fragmented workflows that delay the arrival of statistics by years. The technical direction of travel is clear: automated extraction from electronic health records, standardised coding, and harmonised quality assurance could shorten the lag between diagnosis and data, provided the underlying legal and financial foundations are secure.

The commentary closes with a sentence that doubles as its thesis: we need to count every cancer patient because every patient counts. Timely, rich and high-quality population-based cancer data, the authors argue, are essential for robust monitoring and for evidence-informed European, national and local cancer policies. As Europe prepares to spend hundreds of billions more on cancer care over the coming decades, the unglamorous work of counting cases, staging tumours and tracking survival may prove to be the highest-yield investment of all. The alternative—policy made in the dark—would be far more expensive, and far less equitable, than the registries themselves.

Subject of Research: Strengthening population-based cancer registries in Europe to improve cancer control and monitoring

Article Title: Every cancer patient counts: strengthening European population-based cancer registries to improve cancer control

Article References: Geleijnse, G., Backes, C., Chirlaque, M. D., Sloep, M., Rodon Navarro, E., Šekerija, M., van Eycken, L., & Ursin, G. (2026). Every cancer patient counts: strengthening European population-based cancer registries to improve cancer control. The Lancet Regional Health – Europe, 70, Article 101855. https://doi.org/10.1016/j.lanepe.2026.101855

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101855

Keywords: cancer registries, population-based cancer registries, European Cancer Information System, ECIS, European Network of Cancer Registries, cancer surveillance, Beating Cancer Plan, European Health Data Space, cancer incidence, cancer survival, health policy, Europe

The study, led by Soo Youn Bae of Seoul St. Mary’s Hospital at The Catholic University of Korea and colleagues, examined 696,960 women diagnosed with Stage I–III breast cancer between 1975 and 2021, drawing on the SEER 8 registries, the longest-running and most rigorously maintained cancer surveillance system in the United States. Rather than simply comparing average ages at the beginning and end of the period, the researchers modeled annual trajectories of diagnostic age using weighted ordinary least squares regression, estimating the rate of change—captured as a slope coefficient, β1—for each calendar year across every subgroup. The approach allowed them to detect not just whether diagnostic ages rose or fell, but how fast, at which cancer stage, and for whom.

The headline finding is a profound divergence along socioeconomic lines. Women living in the highest-income census tracts—the top quartile of neighborhood income—experienced significant, sustained increases in their age at diagnosis, consistent with the overall national trend toward later diagnosis. Women in the lowest-income quartile, by contrast, showed stagnant or even declining diagnostic ages. The pattern was particularly stark for Stage II disease: in the lowest-income group, the annual rate of change in diagnostic age was slightly negative, at β1 = −0.028 years per year, meaning that over the 46-year window, the average age at diagnosis for low-income women with Stage II breast cancer effectively moved backward while their wealthier counterparts aged into their diagnoses.

Geography told a parallel story. Women in rural communities, classified using the rural–urban continuum codes that rank counties from most metropolitan to most remote, similarly failed to participate in the national shift toward later diagnosis. Their diagnostic ages remained flat or drifted downward over the study period. The implication is uncomfortable: the demographic transition that has pushed breast cancer into later life for much of the population has simply bypassed the poorest and most geographically isolated women, whose tumors continue to be found at younger ages—and, given the established link between younger age at diagnosis for these groups and later-stage presentation, often at more dangerous points in the disease course.

The racial analysis added a second layer of complexity. Black women in the cohort showed the steepest annual increases in diagnostic age across all tumor stages, a trend that outpaced every other racial group. Yet despite this rapid upward trajectory, Black women remained younger at diagnosis than White women throughout the entire 46-year span. In other words, the fastest improvement in trajectory was not enough to close a persistent gap in the level. The finding captures a well-known paradox in breast cancer epidemiology: Black women are disproportionately diagnosed at younger ages and with more aggressive tumor subtypes, including higher rates of triple-negative and other hormone receptor–negative disease, while simultaneously facing barriers to timely screening and follow-up that delay detection within any given age band.

Why would diagnostic age rise for some groups and stall for others? The authors point to the intertwined machinery of screening access, reproductive and hormonal trends, and health care delivery. The national rise in diagnostic age partly reflects the aging of the population and the widespread adoption of screening mammography, which tends to detect cancers in older women earlier and more often. Mammography uptake, however, has never been evenly distributed. Studies spanning decades have documented lower screening rates among low-income women, rural residents, and some racial and ethnic minority groups, along with longer intervals between abnormal findings and diagnostic resolution. When screening is inconsistent, cancers are more likely to be detected symptomatically—and in groups with higher baseline risks of early-onset disease, that symptomatic detection skews young.

Hormone and reproductive factors plausibly deepen the divide. The rise and fall of menopausal hormone therapy—sharply curtailed after the Women’s Health Initiative reported increased breast cancer risk with combined estrogen plus progestin in 2002—altered incidence patterns, particularly among older, more affluent women who were most likely to use these therapies. Trends toward later childbearing, lower parity, and higher rates of obesity have reshaped risk profiles in ways that differ across socioeconomic strata. Higher-income women have, on balance, experienced risk-factor shifts associated with later-onset disease, while populations facing overlapping disadvantages have carried a heavier burden of early-onset, biologically aggressive tumors. The new trajectory data suggest these two forces have been quietly pulling the age of diagnosis apart for decades.

The technical rigor of the analysis lends weight to its conclusions. By stratifying simultaneously by stage, race, census tract income quartile, and rural–urban continuum code, and by applying weighted regression to annual mean diagnostic ages, the researchers could distinguish genuine temporal trends from artifacts of changing case mix. Stage-specific stratification matters because screening tends to shift the detected-stage distribution: rising diagnostic ages in Stage I disease can reflect early detection in older women, whereas declining or flat diagnostic ages in Stage II–III disease signal that some populations are not being caught by the early-detection net at all. The negative slope for low-income Stage II patients is precisely the signature one would expect if early-onset disease continues to dominate in a population that screening programs have failed to reach.

The policy implications are difficult to ignore. Current screening guidelines in the United States are built around age thresholds—typically recommending that average-risk women begin mammography in their 40s or 50s—implicitly assuming that breast cancer risk rises with age in a broadly uniform way. This study challenges that assumption by showing that the age structure of risk has diverged across social strata. A one-size-fits-all age-based policy, the authors argue, entrenches inequity: it calibrates optimally for high-income metropolitan women, whose diagnostic ages are rising, while under-serving low-income and rural women, whose disease continues to present earlier. Equitable, subgroup-specific screening strategies—whether through risk-adapted starting ages, enhanced outreach in underserved communities, mobile mammography in rural areas, or patient-navigation programs to shorten diagnostic delays—follow directly from the data.

The study also carries a broader lesson about how aggregate statistics can conceal inequality. Had the researchers stopped at the national average, the story would have been one of gradual progress: women, on the whole, are developing breast cancer later, and later diagnosis within a screened population generally correlates with better outcomes. Only by decomposing the trend did the deeper reality emerge—that the benefits of a half-century of progress in cancer detection and care have been distributed unevenly along lines of income, geography, and race. The two-year rise in mean diagnostic age is real, but it is an average of two very different worlds: one where women age into screenings and early detections, and another where cancer arrives early, often between screenings, and frequently at a stage that screening was supposed to prevent. Closing that diagnostic age gap, the authors conclude, is now one of the clearest quantitative targets for achieving equity in breast cancer control.

Subject of Research: Temporal trends in age at breast cancer diagnosis across socioeconomic, racial, and geographic subgroups in the United States from 1975 to 2021

Article Title: Temporal trajectories of age at breast cancer diagnosis by socioeconomic and geographic factors: a 1975–2021 SEER analysis

Article References: Bae, S. Y., Kim, C. W., Chin, J., Lee, J. A., Kim, D., Lee, Y. J., Yoon, C. I., & Park, W.-C. (2026). Temporal trajectories of age at breast cancer diagnosis by socioeconomic and geographic factors: a 1975–2021 SEER analysis. Cancer Causes & Control, 37(10), Article 160. https://doi.org/10.1007/s10552-026-02247-9

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02247-9

Keywords: breast cancer, age at diagnosis, health disparities, socioeconomic factors, SEER, cancer screening, rural health, epidemiology, health equity, mammography, social determinants of health, cancer surveillance